DALLAS – Sept. 23, 2021 – Researchers and data scientists at UT Southwestern Medical Center and The University of Texas MD Anderson Cancer Center have developed an artificial intelligence technique that can identify which cell surface peptides produced by cancer cells called neoantigens are recognized by the immune system. The pMTnet technique, detailed online in Nature Machine Intelligence, could lead to new ways to predict cancer prognosis and potential responsiveness to immunotherapies. "Determining which neoantigens bind to T cell receptors and which don't has seemed like an impossible feat. But with machine learning, we're making progress," said senior author Dr. Tao Wang, Ph.D., Assistant Professor of Population and Data Sciences, and with the Harold C. Simmons Comprehensive Cancer Center and the Center for Genetics of Host Defense at UT Southwestern. Mutations in the genome of cancer cells cause them to display different neoantigens on their surfaces.